Treatment with Antiobesity Drugs in Weight Regain After Bariatric Surgery: a Retrospective Cohort Study
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Citação
OBESITY SURGERY, v.33, n.9, p.2941-2944, 2023
Resumo
Background Bariatric surgery is the most efficient treatment for obesity. However, in some cases, weight regain can occur. Currently, it is unknown the best antiobesity medication (AOM) for such clinical situation. This study aims to evaluate the effect of AOM in patients with weight regain after bariatric surgery. Methods A retrospective cohort study from December 2010 to July 2019 with patients submitted to bariatric surgery that had weight regain and received AOM for at least 2 years. Results Of 96 patients that had weight regain in the analyzed period and received AOM, 16 were excluded from the analysis due to non-compliance (n = 7), treatment failure (n = 5), intolerable side effects with all available AOM (n = 2), or interaction with other medications (n = 2). Eighty patients were included in the analysis. The mean age was 59.0 +/- 10.1 years, 88.8% were female, 91.2% white, and most of them were submitted to gastric bypass (87.6%). The mean preoperative and nadir weight after surgery were 127.9 +/- 25.5 kg and 84.7 +/- 22.8 kg, respectively. At the initiation of AOM, the mean baseline weight was 99.4 +/- 23.1 kg. After 2 years of follow-up, there was significant weight loss in the groups treated with topiramate-alone (- 3.2 kg), topiramate plus sibutramine (- 6.1kg), and orlistat-alone or in combination (- 3.9kg). No statistical difference was observed in the sibutramine- alone group. Conclusion Topiramate (alone or associated with sibutramine) and orlistat (alone or in combination) promoted significant weight loss after 2 years of use in patients submitted to bariatric surgery with weight regain.
Palavras-chave
Bariatric surgery, Weight regain, Obesity, Topiramate, Orlistat, Sibutramine
Referências
- Brown CS, 2021, EPILEPSY BEHAV REP, V16, DOI 10.1016/j.ebr.2021.100439
- Cooper TC, 2015, OBES SURG, V25, P1474, DOI 10.1007/s11695-014-1560-z
- Edgerton C, 2021, J GASTROINTEST SURG, V25, P369, DOI 10.1007/s11605-020-04880-4
- Halpern B, 2022, ARCH ENDOCRIN METAB, V66, DOI 10.20945/2359-3997000000465
- Jensen AB, 2023, OBES SURG, V33, P1017, DOI 10.1007/s11695-023-06484-8
- Lucas E, 2023, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1043595
- Murvelashvili N, 2023, OBESITY, V31, P1280, DOI 10.1002/oby.23736
- Noria SF, 2023, CURR DIABETES REP, V23, P31, DOI 10.1007/s11892-023-01498-z
- Pi-Sunyer X, 2015, NEW ENGL J MED, V373, P11, DOI 10.1056/NEJMoa1411892